Abstract 18496: Trends in Healthcare Expenditures and Cardiovascular Risk Profile Among Individuals Without ASCVD: Analysis of the Medical Expenditure Panel Survey 2002-2013
Introduction: American Heart Association 2020 Strategic Goals emphasize the importance of optimizing cardiovascular modifiable risk factor (CRF) profile to diminish burden of CV disease. In this study we aimed to quantify the trends in expenditures and expenditures by CRF profiles among individuals without ASCVD.
Methods: Data were obtained annually from 2002-2013 using publicly available household component file of Medical Expenditure Panel Survey (MEPS) database. ASCVD risk factors (hypertension, diabetes mellitus, hypercholesterolemia, smoking, physical activity & obesity) were ascertained by ICD-9-CM codes and self-report. CRF profile was then categorized as “Optimal”, “Average” and “Poor” (0-1, 2-3 & ≥ 4 CRF, respectively). Individuals with established ASCVD, < 40 years of age and BMI < 18.5 kg/m2 were excluded. Full-year consolidated data files were used to generate estimates of annual healthcare expenditures. All analyses took into account MEPS complex design; costs were adjusted to 2013 USD using Gross Domestic Product Index.
Results: Optimal profile prevalence decreased from 48% in 2002-2003 to 41% in 2012-2013. During the same period, average and poor profiles increased (42% to 45% and 11% to 14%, respectively). Mean adjusted per capita healthcare expenditures among those with poor CRF profile was $6192 [95% CI 5747-6638] in 2002-2003 vs. $6886 [95% CI 6183-7588] in 2012-2013). In pooled data over 12 years, after adjusting for confounding variables, as compared to those with poor CRF profile, costs for average and optimal profiles were significantly lower by $2,412 & $3,744, respectively.
Conclusions: Favorable CRF profile is associated with lower per capita expenditures among individuals without established ASCVD. Our findings support AHA strategic emphasis on optimizing CRF profile not only to reduce future risk of clinical ASCVD but also to favorably impact economic burden of managing with these risk factors.
Author Disclosures: J. Valero-Elizondo: None. J.A. Salami: None. H.J. Warraich: None. O. Ogunmoroti: None. E.S. Spatz: None. N. Desai: None. J.S. Rana: None. S.S. Virani: None. R. Blankstein: None. M.J. Blaha: None. K. Nasir: Consultant/Advisory Board; Modest; Quest Diagnostic, Regeneron.
- © 2016 by American Heart Association, Inc.